January 26, 2018 06:03 AM EST

Trailing GSK, AstraZeneca offers an encouraging look at PhIII data for three-in-one COPD inhaler

Amber Tong

AstraZeneca $AZN started the day with news that its three-in-one chronic obstructive pulmonary disease inhaler has turned out positive top-line results in a Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Trailing GSK, AstraZeneca offers an encouraging look at PhIII data for three-in-one COPD inhaler

Amber Tong

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Trail­ing GSK, As­traZeneca of­fers an en­cour­ag­ing look at PhI­II da­ta for three-in-one COPD in­haler

Amber Tong

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Trailing GSK, AstraZeneca offers an encouraging look at PhIII data for three-in-one COPD inhaler

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties